ClinicalTrials.gg
CompletedNCT00920218Updated Dec 12, 2017Results posted

Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A

A Phase 2 interventional study of Herpes Zoster Vaccine 1437173A and Placebo vaccine (saline) in Herpes Zoster, sponsored by GlaxoSmithKline. Completed at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-12.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
121
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.

Enrollment
31st of 46
121 · median 239
Started
2009
with 1 other
Phase 2
8 of 46
1 open now
Registered
2nd of 46
by date
Lead sponsor
26 of 46
GlaxoSmithKline

Among the 46 studies testing shingrix in Herpes Zoster, this one is the 31st largest by enrollment, is one of 2 that started in 2009, is one of 8 in phase 2, and was the 2nd registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About shingrix

shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing shingrix in Herpes Zoster, or all of them as a file.
02

Study summary

The purpose of this observer-blind study is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' investigational Herpes Zoster vaccine GSK1437173A when administered as 2 doses or 3 doses to hematopoietic stem cell transplant (HCT) recipients.

Read the detailed description

The Protocol Posting has been updated following Protocol amendment 2, Sep 2009. The sections impacted are: eligibility criteria.

03

Conditions studied

  • Herpes Zoster

Browse trials for

Keywords

  • Vaccine
  • Safety
  • Herpes Zoster
  • Immunogenicity
  • Stem cell transplantation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who the investigator believes that they can and will comply with the requirements of the protocol;
  • Male and female subjects at least 18 years old at the time of vaccination;
  • Serological evidence of prior VZV infection for all subjects born in 1980 or later and for subjects born outside the US before 1980 in a tropical or sub-tropical region. No testing for serological evidence of prior VZV infection is required for US subjects born before 1980;
  • Has undergone HCT within the past 50-70 days for treatment of Hodgkin lymphoma, non-Hodgkin lymphoma (T or B cell), myeloma or acute myeloid leukemia, and there are no plans for additional HCTs
  • Written obtained from the subject;
  • If the subject is female, she must be of non- or if she is of childbearing potential, she must practice adequate for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for 2 months after completion of the vaccination series.

Exclusion criteria

Exclusion Criteria:

  • Use of any non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period;
  • Administration or planned administration of a vaccine that is not part of the study protocol since transplantation. However licensed non-replicating vaccines (i.e. inactivated and subunit vaccines, including inactivated and subunit influenza vaccines, with or without adjuvant) may be administered up to 8 days prior to dose 1;
  • Administration of immunoglobulins since transplantation;
  • Previous vaccination against varicella or HZ;
  • History of HZ within the previous 12 months;
  • Known exposure to VZV since transplantation;
  • Evidence of active infection at the time of enrollment including a temperature of ≥ 37.5° C or any serious HCT-related complication;
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine;
  • or intolerance to acyclovir or valacyclovir;
  • Pregnant or lactating female.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
121 participants (actual)

Study arms

  • Experimental
    GSK 1437173A F1 Group

    Male or female subjects, 18 years of age or older at the time of the first vaccination, received 3 doses of GSK 1437173A formulation 1 (F1) vaccine, administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule.

    Biological: Herpes Zoster Vaccine 1437173A

  • Experimental
    GSK 1437173A F2 Group

    Male or female subjects, 18 years of age or older at the time of the first vaccination, received 3 doses of GSK 1437173A formulation 2 (F2) vaccine, administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule.

    Biological: Herpes Zoster Vaccine 1437173A

  • Experimental
    Placebo-GSK 1437173A F1 Group

    Male or female subjects, 18 years of age or older at the time of the first vaccination, received 1 dose of the placebo followed by 2 doses of GSK 1437173A F1 vaccine. For some safety analyses, this Group was split into Placebo 1D Group (results following placebo administration) and GSK 1437173A 2D Group (results following HZV administration). All vaccines were administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule.

    Biological: Herpes Zoster Vaccine 1437173A · Biological: Placebo vaccine (saline)

  • Placebo comparator
    Placebo Group

    Male or female subjects, 18 years of age or older at the time of the first vaccination, received 3 doses of placebo, administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule.

    Biological: Placebo vaccine (saline)

Interventions

  • Different formulations of investigational vaccine (GSK 1437173A) administered in 2 or 3 doses intramuscularly.

  • BiologicalPlacebo vaccine (saline)

    1 or 3 doses of Placebo (saline) injected intramuscularly.

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Any and Grade 3 Solicited Local Symptoms

    Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

    Time frame: During the 7-days (Days 0-6) post-vaccination period following each dose and across doses

  2. Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms

    Assessed solicited general symptoms were fatigue, gastrointestinal symptoms \[including nausea, vomiting, diarrhoea and abdominal pain\], temperature \[defined as oral temperature equal to or above (≥) 37.5 degrees Celsius (°C)\], headache and myalgia. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 temperature = temperature higher than (\>) 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

    Time frame: During the 7-days (Days 0-6) post-vaccination period following each dose and across doses

  3. Number of Subjects With Any and Grade 3 Unsolicited Adverse Events (AEs)

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities.

    Time frame: During the 30-day (Days 0-29) post-vaccination period

  4. Number of Subjects With Serious Adverse Events (SAEs)

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: Any time during the study up to Day 29 after the last vaccination

  5. Number of Subjects With Serious Adverse Events (SAEs)

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: During the entire study period (from Day 0 up to Month 15)

  6. Number of Subjects With Any New Onset of Autoimmune Diseases (NOADs) and Other Immune Mediated Inflammatory Disorders

    Any new onset of autoimmune diseases and immune mediated inflammatory disorders were to be reported throughout the entire study period, whether or not they were considered to be possibly related to the treatment administration. These included neurological/demyelinating events, rheumatic and connective diseases, autoimmune endocrine diseases, inflammatory bowel diseases, autoimmune blood disorders, inflammatory skin disorders, other autoimmune/inflammatory events, autoimmune bullous skin diseases, vasculitis and liver autoimmune diseases.

    Time frame: Within the 30-day (Days 0-29) post last vaccination period

  7. Number of Subjects With Any New Onset of Autoimmune Diseases (NOADs) and Other Immune Mediated Inflammatory Disorders

    Any new onset of autoimmune diseases and immune mediated inflammatory disorders were to be reported throughout the entire study period, whether or not they were considered to be possibly related to the treatment administration. These included neurological/demyelinating events, rheumatic and connective diseases, autoimmune endocrine diseases, inflammatory bowel diseases, autoimmune blood disorders, inflammatory skin disorders, other autoimmune/inflammatory events, autoimmune bullous skin diseases, vasculitis and liver autoimmune diseases.

    Time frame: During the entire study period (from Day 0 to Month 15)

  8. Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges

    Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hemoglobin (HGB), Hematocrit (HCT), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Monocytes (MON), Neutrophils (NEU), Platelets (PLAT), Prothrombin Time (PT), Partial Thromboplastin Time (PTT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).

    Time frame: At Month 0

  9. Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges

    Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hemoglobin (HGB), Hematocrit (HCT), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Monocytes (MON), Neutrophils (NEU), Platelets (PLAT), Prothrombin Time (PT), Partial Thromboplastin Time (PTT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).

    Time frame: At Month 1

  10. Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges

    Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hemoglobin (HGB), Hematocrit (HCT), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Monocytes (MON), Neutrophils (NEU), Platelets (PLAT), Prothrombin Time (PT), Partial Thromboplastin Time (PTT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).

    Time frame: At Month 2

  11. Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges

    Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hemoglobin (HGB), Hematocrit (HCT), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Monocytes (MON), Neutrophils (NEU), Platelets (PLAT), Prothrombin Time (PT), Partial Thromboplastin Time (PTT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).

    Time frame: At Month 3

  12. Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges

    Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hemoglobin (HGB), Hematocrit (HCT), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Monocytes (MON), Neutrophils (NEU), Platelets (PLAT), Prothrombin Time (PT), Partial Thromboplastin Time (PTT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).

    Time frame: At Month 4

  13. Frequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines

    The analysis focused on CD4 T-cells expressing at least 2 cytokines among Interferon gamma \[IFN-γ\], Interleukin 2 \[IL-2\], Tumour Necrosis Factor alpha \[TNF-α\] and/or CD40 Ligand \[CD40L\] as determined by in vitro intracellular cytokine staining (ICS).

    Time frame: At Month 4

  14. Anti-glycoprotein E (Anti-gE) Geometric Mean Antibody Concentrations

    Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL).

    Time frame: At Month 4

  15. Anti-gE Mean Antibody Concentrations

    Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as mean concentrations, expressed in milli-international units per milliliter (mIU/mL).

    Time frame: At Month 4

Secondary outcomes

  1. Frequency of CD4 T-cells Specific for Varicella Zoster Virus (VZV) Antigens

    The analysis focused on CD4 T-cells expressing at least 2 cytokines among Interferon gamma \[IFN-γ\], Interleukin 2 \[IL-2\], Tumour Necrosis Factor alpha \[TNF-α\] and/or CD40 Ligand \[CD40L\] as determined by in vitro intracellular cytokine staining (ICS).

    Time frame: At Months 0, 1, 2, 3, 4 and 15

  2. Frequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines

    The analysis focused on CD4 T-cells expressing at least 2 cytokines among Interferon gamma \[IFN-γ\], Interleukin 2 \[IL-2\], Tumour Necrosis Factor alpha \[TNF-α\] and/or CD40 Ligand \[CD40L\] as determined by in vitro intracellular cytokine staining (ICS).

    Time frame: At Months 0, 1, 2, 3 and 15

  3. Varicella Zoster Virus (VZV)-Specific Geometric Mean Antibody Concentrations

    Concentrations are presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL).

    Time frame: At Months 0, 1, 2, 3, 4 and 15

  4. VZV-specific Mean Antibody Concentrations

    Concentrations are presented as mean concentrations, expressed in milli-international units per milliliter (mIU/mL).

    Time frame: At Months 0, 1, 2, 3, 4 and 15

  5. Anti-gE Geometric Mean Antibody Concentrations

    Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL).

    Time frame: At Months 0, 1, 2, 3 and 15

  6. Anti-gE Mean Antibody Concentrations

    Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as mean concentrations, expressed in milli-international units per milliliter (mIU/mL).

    Time frame: At Months 0, 1, 2, 3 and 15

  7. Number of Subjects With Confirmed Herpes Zoster (HZ) Cases

    A suspected case of HZ could be confirmed by PCR and/or by clinical review of the GSK physician responsible for the study. Rash lesion samples collected from subjects clinically diagnosed as having a suspected case of HZ were tested by by polymerase chain reaction (PCR) using standardized and validated procedures for the laboratory diagnosis of HZ. If the PCR specimen was inadequate or was missing, suspected HZ cases were to be classified as 'a confirmed case of HZ' or 'not a case of HZ' based on the determination by the GSK responsible physician of the study.

    Time frame: During the entire study period (from Day 0 to Month 15)

07

Results

Posted Dec 12, 2017

Participant flow

Serological evidence of prior Varicella-Zoster Virus infection for those born in 1980 or later and for those born outside the US before 1980 in a tropical or sub-tropical region was required. All subjects were to have undergone autologous hematopoietic stem cell transplantation (HCT) within the past 50-70 days; and had no additional HCTs planned.

Participant flow — Overall Study
MilestoneGSK 1437173A F1 GroupGSK 1437173A F2 GroupPlacebo-GSK 1437173A F1 GroupPlacebo Group
Started30293130
Completed28242323
Not completed2587
Withdrew: Serious adverse event2021
Withdrew: Withdrawal by subject0320
Withdrew: Migrated/moved from study area0010
Withdrew: Lost to follow-up0103
Withdrew: Transplant failed/malignancy recurrence0123
Withdrew: Other0010

Outcome measures

PrimaryNumber of Subjects With Any and Grade 3 Solicited Local Symptoms

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

Time frame:
During the 7-days (Days 0-6) post-vaccination period following each dose and across doses
Reported as:
Count of participants · Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
ParticipantsGSK 1437173A F1 GroupGSK 1437173A F2 GroupGSK 1437173A 2D GroupPlacebo 1D GroupPlacebo Group
Any Pain, Dose 125192243
Grade 3 Pain, Dose 103100
Any Redness, Dose 126210
Grade 3 Redness, Dose 100000
Any Swelling, Dose 113400
Grade 3 Swelling, Dose 100000
Any Pain, Dose 2241922—3
Grade 3 Pain, Dose 2231—0
Any Redness, Dose 2227—1
Grade 3 Redness, Dose 2000—0
Any Swelling, Dose 2113—0
Grade 3 Swelling, Dose 2000—0
Any Pain, Dose 32415——4
Grade 3 Pain, Dose 310——0
Any Redness, Dose 364——0
Grade 3 Redness, Dose 300——0
Any Swelling, Dose 341——0
Grade 3 Swelling, Dose 300——0
Any Pain, Across Doses27222447
Grade 3 Pain, Across Doses35100
Any Redness, Across Doses67711
Grade 3 Redness, Across Doses00000
Any Swelling, Across Doses64400
Grade 3 Swelling, Across Doses00000
PrimaryNumber of Subjects With Any, Grade 3 and Related Solicited General Symptoms

Assessed solicited general symptoms were fatigue, gastrointestinal symptoms \[including nausea, vomiting, diarrhoea and abdominal pain\], temperature \[defined as oral temperature equal to or above (≥) 37.5 degrees Celsius (°C)\], headache and myalgia. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 temperature = temperature higher than (\>) 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

Time frame:
During the 7-days (Days 0-6) post-vaccination period following each dose and across doses
Reported as:
Count of participants · Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
ParticipantsGSK 1437173A F1 GroupGSK 1437173A F2 GroupGSK 1437173A 2D GroupPlacebo 1D GroupPlacebo Group
Any Fatigue, Dose 1131112157
Grade 3 Fatigue, Dose 111010
Related Fatigue, Dose 157861
Any Gastr. sympt., Dose 164192
Grade 3 Gastr. sympt., Dose 100000
Related Gastr. sympt., Dose 132131
Any Headache, Dose 141472
Grade 3 Headache, Dose 100000
Related Headache, Dose 131421
Any Myalgia, Dose 114121393
Grade 3 Myalgia, Dose 110100
Related Myalgia, Dose 11291062
Any Temperature, Dose 133571
Grade 3 Temperature, Dose 100020
Related Temperature, Dose 132451
Any Fatigue, Dose 210816—8
Grade 3 Fatigue, Dose 2311—0
Related Fatigue, Dose 27310—3
Any Gastr. sympt., Dose 2226—2
Grade 3 Gastr. sympt., Dose 2001—0
Related Gastr. sympt., Dose 2122—0
Any Headache, Dose 2716—2
Grade 3 Headache, Dose 2200—0
Related Headache, Dose 2404—1
Any Myalgia, Dose 2131319—5
Grade 3 Myalgia, Dose 2421—0
Related Myalgia, Dose 2121112—3
Any Temperature, Dose 21044—1
Grade 3 Temperature, Dose 2000—0
Related Temperature, Dose 2834—0
Any Fatigue, Dose 31510——8
Grade 3 Fatigue, Dose 330——1
Related Fatigue, Dose 398——3
Any Gastr. sympt., Dose 395——2
Grade 3 Gastr. sympt., Dose 300——0
Related Gastr. sympt., Dose 343——1
Any Headache, Dose 3121——4
Grade 3 Headache, Dose 320——0
Related Headache, Dose 391——3
Any Myalgia, Dose 3187——5
Grade 3 Myalgia, Dose 340——1
Related Myalgia, Dose 3147——4
Any Temperature, Dose 363——2
Grade 3 Temperature, Dose 310——0
Related Temperature, Dose 363——1
Any Fatigue, Across Doses1818201510
Grade 3 Fatigue, Across Doses42111
Related Fatigue, Across Doses11111465
Any Gastr. sympt., Across Doses107694
Grade 3 Gastr. sympt., Across Doses00100
Related Gastr. sympt., Across Doses75232
Any Headache, Across Doses133976
Grade 3 Headache, Across Doses30000
Related Headache, Across Doses92725
Any Myalgia, Across Doses21182298
Grade 3 Myalgia, Across Doses82101
Related Myalgia, Across Doses19151665
Any Temperature, Across Doses128874
Grade 3 Temperature, Across Doses10020
Related Temperature, Across Doses107752
PrimaryNumber of Subjects With Any and Grade 3 Unsolicited Adverse Events (AEs)

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities.

Time frame:
During the 30-day (Days 0-29) post-vaccination period
Reported as:
Count of participants · Participants
Number of Subjects With Any and Grade 3 Unsolicited Adverse Events (AEs)
ParticipantsGSK 1437173A F1 GroupGSK 1437173A F2 GroupGSK 1437173A 2D GroupPlacebo 1D GroupPlacebo Group
Any AEs2523221621
Grade 3 AEs56214
PrimaryNumber of Subjects With Serious Adverse Events (SAEs)

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame:
Any time during the study up to Day 29 after the last vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Serious Adverse Events (SAEs)
ParticipantsGSK 1437173A F1 GroupGSK 1437173A F2 GroupGSK 1437173A 2D GroupPlacebo 1D GroupPlacebo Group
Number of Subjects With Serious Adverse Events (SAEs)35212
PrimaryNumber of Subjects With Serious Adverse Events (SAEs)

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame:
During the entire study period (from Day 0 up to Month 15)
Reported as:
Count of participants · Participants
Number of Subjects With Serious Adverse Events (SAEs)
ParticipantsGSK 1437173A F1 GroupGSK 1437173A F2 GroupPlacebo-GSK 1437173A F1 GroupPlacebo Group
Number of Subjects With Serious Adverse Events (SAEs)69108
PrimaryNumber of Subjects With Any New Onset of Autoimmune Diseases (NOADs) and Other Immune Mediated Inflammatory Disorders

Any new onset of autoimmune diseases and immune mediated inflammatory disorders were to be reported throughout the entire study period, whether or not they were considered to be possibly related to the treatment administration. These included neurological/demyelinating events, rheumatic and connective diseases, autoimmune endocrine diseases, inflammatory bowel diseases, autoimmune blood disorders, inflammatory skin disorders, other autoimmune/inflammatory events, autoimmune bullous skin diseases, vasculitis and liver autoimmune diseases.

Time frame:
Within the 30-day (Days 0-29) post last vaccination period
Reported as:
Count of participants · Participants
Number of Subjects With Any New Onset of Autoimmune Diseases (NOADs) and Other Immune Mediated Inflammatory Disorders
ParticipantsGSK 1437173A F1 GroupGSK 1437173A F2 GroupPlacebo-GSK 1437173A F1 GroupPlacebo Group
Number of Subjects With Any New Onset of Autoimmune Diseases (NOADs) and Other Immune Mediated Inflammatory Disorders0000
PrimaryNumber of Subjects With Any New Onset of Autoimmune Diseases (NOADs) and Other Immune Mediated Inflammatory Disorders

Any new onset of autoimmune diseases and immune mediated inflammatory disorders were to be reported throughout the entire study period, whether or not they were considered to be possibly related to the treatment administration. These included neurological/demyelinating events, rheumatic and connective diseases, autoimmune endocrine diseases, inflammatory bowel diseases, autoimmune blood disorders, inflammatory skin disorders, other autoimmune/inflammatory events, autoimmune bullous skin diseases, vasculitis and liver autoimmune diseases.

Time frame:
During the entire study period (from Day 0 to Month 15)
Reported as:
Count of participants · Participants
Number of Subjects With Any New Onset of Autoimmune Diseases (NOADs) and Other Immune Mediated Inflammatory Disorders
ParticipantsGSK 1437173A F1 GroupGSK 1437173A F2 GroupPlacebo-GSK 1437173A F1 GroupPlacebo Group
Number of Subjects With Any New Onset of Autoimmune Diseases (NOADs) and Other Immune Mediated Inflammatory Disorders0000
PrimaryNumber of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges

Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hemoglobin (HGB), Hematocrit (HCT), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Monocytes (MON), Neutrophils (NEU), Platelets (PLAT), Prothrombin Time (PT), Partial Thromboplastin Time (PTT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).

Time frame:
At Month 0
Reported as:
Count of participants · Participants
Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges
ParticipantsGSK 1437173A F1 GroupGSK 1437173A F2 GroupPlacebo-GSK 1437173A F1 GroupPlacebo Group
ALT — Unknown0000
ALT — Below0000
ALT — Normal28293129
ALT — Above2001
AST — Unknown0011
AST — Below0000
AST — Normal29292928
AST — Above1011
BAS — Unknown0001
BAS — Below0000
BAS — Normal30293129
BAS — Above0000
CAL — Unknown0011
CAL — Below0213
CAL — Normal30272926
CAL — Above0000
CREA — Unknown0000
CREA — Below1011
CREA — Normal28252727
CREA — Above1432
EOS — Unknown0001
EOS — Below5166
EOS — Normal24282321
EOS — Above1022
FIBR — Unknown2014
FIBR — Below3050
FIBR — Normal25222124
FIBR — Above0742
HGB — Unknown0001
HGB — Below22222723
HGB — Normal8746
HGB — Above0000
HCT — Unknown0101
HCT — Below23212725
HCT — Normal7744
HCT — Above0000
LDH — Unknown0010
LDH — Below0000
LDH — Normal28282927
LDH — Above2113
LYM — Unknown0001
LYM — Below111469
LYM — Normal19152319
LYM — Above0021
MON — Unknown0001
MON — Below3412
MON — Normal27253027
MON — Above0000
NEU — Unknown0001
NEU — Below4373
NEU — Normal26252326
NEU — Above0110
PLAT — Unknown0001
PLAT — Below26610
PLAT — Normal28232519
PLAT — Above0000
PT — Unknown2014
PT — Below0000
PT — Normal27283025
PT — Above1101
PTT — Unknown2014
PTT — Below0100
PTT — Normal27242722
PTT — Above1434
RBC — Unknown0101
RBC — Below24252926
RBC — Normal6323
RBC — Above0000
TP — Unknown0000
TP — Below5387
TP — Normal25262323
TP — Above0000
WBC — Unknown0001
WBC — Below9896
WBC — Normal21202022
WBC — Above0121
PrimaryNumber of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges

Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hemoglobin (HGB), Hematocrit (HCT), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Monocytes (MON), Neutrophils (NEU), Platelets (PLAT), Prothrombin Time (PT), Partial Thromboplastin Time (PTT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).

Time frame:
At Month 1
Reported as:
Count of participants · Participants
Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges
ParticipantsGSK 1437173A F1 GroupGSK 1437173A F2 GroupPlacebo-GSK 1437173A F1 GroupPlacebo Group
ALT — Unknown0010
ALT — Below0000
ALT — Normal26282927
ALT — Above4103
AST — Unknown0011
AST — Below0000
AST — Normal25292927
AST — Above5002
BAS — Unknown0110
BAS — Below0000
BAS — Normal30282930
BAS — Above0000
CAL — Unknown0011
CAL — Below1201
CAL — Normal29262928
CAL — Above0100
CREA — Unknown0010
CREA — Below0000
CREA — Normal29272627
CREA — Above1233
EOS — Unknown0110
EOS — Below7687
EOS — Normal23221922
EOS — Above0021
FIBR — Unknown0101
FIBR — Below3205
FIBR — Normal24202622
FIBR — Above3642
HGB — Unknown0110
HGB — Below19182325
HGB — Normal111065
HGB — Above0000
HCT — Unknown0110
HCT — Below22192425
HCT — Normal8955
HCT — Above0000
LDH — Unknown0011
LDH — Below0000
LDH — Normal30282927
LDH — Above0102
LYM — Unknown0110
LYM — Below111389
LYM — Normal19152121
LYM — Above0000
MON — Unknown0110
MON — Below8525
MON — Normal22222725
MON — Above0100
NEU — Unknown0110
NEU — Below6956
NEU — Normal24192423
NEU — Above0001
PLAT — Unknown0111
PLAT — Below5457
PLAT — Normal25242422
PLAT — Above0000
PT — Unknown0101
PT — Below0000
PT — Normal28252928
PT — Above2311
PTT — Unknown0101
PTT — Below0100
PTT — Normal26232626
PTT — Above4443
RBC — Unknown0110
RBC — Below24242529
RBC — Normal6441
RBC — Above0000
TP — Unknown0010
TP — Below3266
TP — Normal27272324
TP — Above0000
WBC — Unknown0110
WBC — Below1310813
WBC — Normal17172116
WBC — Above0101
PrimaryNumber of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges

Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hemoglobin (HGB), Hematocrit (HCT), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Monocytes (MON), Neutrophils (NEU), Platelets (PLAT), Prothrombin Time (PT), Partial Thromboplastin Time (PTT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).

Time frame:
At Month 2
Reported as:
Count of participants · Participants
Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges
ParticipantsGSK 1437173A F1 GroupGSK 1437173A F2 GroupPlacebo-GSK 1437173A F1 GroupPlacebo Group
ALT — Unknown1100
ALT — Below0000
ALT — Normal26262924
ALT — Above3104
AST — Unknown1100
AST — Below0000
AST — Normal28262926
AST — Above1102
BAS — Unknown1001
BAS — Below0000
BAS — Normal29282927
BAS — Above0000
CAL — Unknown1100
CAL — Below1000
CAL — Normal27262827
CAL — Above1111
CREA — Unknown1100
CREA — Below0000
CREA — Normal28252625
CREA — Above1233
EOS — Unknown1001
EOS — Below7751
EOS — Normal21212225
EOS — Above1021
FIBR — Unknown1101
FIBR — Below4044
FIBR — Normal23242321
FIBR — Above2322
HGB — Unknown1001
HGB — Below17152019
HGB — Normal121398
HGB — Above0000
HCT — Unknown1001
HCT — Below20182121
HCT — Normal91086
HCT — Above0000
LDH — Unknown1100
LDH — Below0000
LDH — Normal28242926
LDH — Above1302
LYM — Unknown1001
LYM — Below101445
LYM — Normal19142522
LYM — Above0000
MON — Unknown1001
MON — Below4525
MON — Normal24232722
MON — Above1000
NEU — Unknown1001
NEU — Below6463
NEU — Normal23232324
NEU — Above0100
PLAT — Unknown1001
PLAT — Below3457
PLAT — Normal26242420
PLAT — Above0000
PT — Unknown1101
PT — Below0010
PT — Normal27252826
PT — Above2201
PTT — Unknown1101
PTT — Below0010
PTT — Normal23222425
PTT — Above6542
RBC — Unknown1001
RBC — Below22192422
RBC — Normal7955
RBC — Above0000
TP — Unknown1100
TP — Below2143
TP — Normal27262525
TP — Above0000
WBC — Unknown1001
WBC — Below9976
WBC — Normal20182221
WBC — Above0100
PrimaryNumber of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges

Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hemoglobin (HGB), Hematocrit (HCT), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Monocytes (MON), Neutrophils (NEU), Platelets (PLAT), Prothrombin Time (PT), Partial Thromboplastin Time (PTT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).

Time frame:
At Month 3
Reported as:
Count of participants · Participants
Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges
ParticipantsGSK 1437173A F1 GroupGSK 1437173A F2 GroupPlacebo-GSK 1437173A F1 GroupPlacebo Group
ALT — Unknown0010
ALT — Below0000
ALT — Normal25262727
ALT — Above3102
AST — Unknown0010
AST — Below0000
AST — Normal27262728
AST — Above1101
BAS — Unknown3101
BAS — Below0000
BAS — Normal25262827
BAS — Above0001
CAL — Unknown0010
CAL — Below1002
CAL — Normal27272626
CAL — Above0011
CREA — Unknown0010
CREA — Below0000
CREA — Normal28252426
CREA — Above0233
EOS — Unknown3101
EOS — Below4545
EOS — Normal20212220
EOS — Above1023
FIBR — Unknown1000
FIBR — Below1334
FIBR — Normal20212124
FIBR — Above6341
HGB — Unknown3101
HGB — Below11131418
HGB — Normal14131410
HGB — Above0000
HCT — Unknown3101
HCT — Below13152018
HCT — Normal1211810
HCT — Above0000
LDH — Unknown0010
LDH — Below0000
LDH — Normal28272727
LDH — Above0002
LYM — Unknown3101
LYM — Below913710
LYM — Normal16132118
LYM — Above0000
MON — Unknown3101
MON — Below2625
MON — Normal23202623
MON — Above0000
NEU — Unknown3101
NEU — Below3365
NEU — Normal21212223
NEU — Above1200
PLAT — Unknown3201
PLAT — Below2358
PLAT — Normal23222320
PLAT — Above0000
PT — Unknown1000
PT — Below0010
PT — Normal25252727
PT — Above2202
PTT — Unknown1000
PTT — Below0010
PTT — Normal20232225
PTT — Above7454
RBC — Unknown3101
RBC — Below15172224
RBC — Normal10964
RBC — Above0000
TP — Unknown0010
TP — Below2334
TP — Normal26242424
TP — Above0001
WBC — Unknown3101
WBC — Below8977
WBC — Normal16172121
WBC — Above1000
PrimaryNumber of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges

Hematological and biochemical parameters assessed were Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Basophils (BAS), Calcium (CAL), Creatinine (CREA), Eosinophils (EOS), Fibrinogen (FIBR), Hemoglobin (HGB), Hematocrit (HCT), Lactate Dehydrogenase (LDH), Lymphocytes (LYM), Monocytes (MON), Neutrophils (NEU), Platelets (PLAT), Prothrombin Time (PT), Partial Thromboplastin Time (PTT), Red Blood Cells (RBC), Total Protein (TP) and White Blood Cells (WBC).

Time frame:
At Month 4
Reported as:
Count of participants · Participants
Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges
ParticipantsGSK 1437173A F1 GroupGSK 1437173A F2 GroupPlacebo-GSK 1437173A F1 GroupPlacebo Group
ALT — Unknown1000
ALT — Below0000
ALT — Normal26262725
ALT — Above2001
AST — Unknown1100
AST — Below0000
AST — Normal28252724
AST — Above0002
BAS — Unknown1000
BAS — Below0000
BAS — Normal28262726
BAS — Above0000
CAL — Unknown1000
CAL — Below3001
CAL — Normal25262725
CAL — Above0000
CREA — Unknown1000
CREA — Below0000
CREA — Normal27232525
CREA — Above1321
EOS — Unknown1000
EOS — Below3432
EOS — Normal24212322
EOS — Above1112
FIBR — Unknown0100
FIBR — Below4324
FIBR — Normal16192222
FIBR — Above9330
HGB — Unknown0000
HGB — Below17111420
HGB — Normal1215136
HGB — Above0000
HCT — Unknown0000
HCT — Below18141720
HCT — Normal1112106
HCT — Above0000
LDH — Unknown1100
LDH — Below0000
LDH — Normal26242625
LDH — Above2111
LYM — Unknown1000
LYM — Below71096
LYM — Normal21161819
LYM — Above0001
MON — Unknown1000
MON — Below6245
MON — Normal22242321
MON — Above0000
NEU — Unknown1000
NEU — Below4274
NEU — Normal23242022
NEU — Above1000
PLAT — Unknown0000
PLAT — Below4569
PLAT — Normal25212117
PLAT — Above0000
PT — Unknown0100
PT — Below0010
PT — Normal27232623
PT — Above2203
PTT — Unknown0100
PTT — Below0010
PTT — Normal27222020
PTT — Above2366
RBC — Unknown0000
RBC — Below21152323
RBC — Normal81143
RBC — Above0000
TP — Unknown1000
TP — Below3113
TP — Normal25252623
TP — Above0000
WBC — Unknown1000
WBC — Below8789
WBC — Normal19191916
WBC — Above1001
PrimaryFrequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines

The analysis focused on CD4 T-cells expressing at least 2 cytokines among Interferon gamma \[IFN-γ\], Interleukin 2 \[IL-2\], Tumour Necrosis Factor alpha \[TNF-α\] and/or CD40 Ligand \[CD40L\] as determined by in vitro intracellular cytokine staining (ICS).

Time frame:
At Month 4
Reported as:
Mean · gE-specific CD4+ T-cells/million T-cells
Frequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines
gE-specific CD4+ T-cells/million T-cellsGSK 1437173A F1 GroupGSK 1437173A F2 GroupPlacebo-GSK 1437173A F1 GroupPlacebo Group
Frequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines11963.56 ± 11655.098114.83 ± 9957.556974.97 ± 10437.5396.15 ± 108.08
Statistical analysis
  • GSK 1437173A F1 Group · Dunnett for multiple comparisons · p = <0.0001 · Fold increase over control: 32.31 · 76.16% CI 20.65 to 50.54
  • Placebo-GSK 1437173A F1 Group · Dunnett for multiple comparisons · p = <0.0001 · Fold increase over control: 9.51 · 76.16% CI 6.07 to 14.9
PrimaryAnti-glycoprotein E (Anti-gE) Geometric Mean Antibody Concentrations

Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL).

Time frame:
At Month 4
Reported as:
Geometric mean · mIU/mL
Anti-glycoprotein E (Anti-gE) Geometric Mean Antibody Concentrations
mIU/mLGSK 1437173A F1 GroupGSK 1437173A F2 GroupPlacebo-GSK 1437173A F1 GroupPlacebo Group
Anti-glycoprotein E (Anti-gE) Geometric Mean Antibody Concentrations29192.9 (11004.7 to 77442.1)22503.0 (8432.7 to 60050.2)11064.6 (4361.2 to 28071.8)406.0 (244.2 to 674.9)
Statistical analysis
  • GSK 1437173A F1 Group · Dunnett for multiple comparisons · p = <0.0001 · Fold increase over control: 74.41 · 76.16% CI 33.12 to 167.17
  • Placebo-GSK 1437173A F1 Group · Dunnett for multiple comparisons · p = <0.0001 · Fold increase over control: 42.20 · 76.16% CI 20.20 to 88.13
PrimaryAnti-gE Mean Antibody Concentrations

Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as mean concentrations, expressed in milli-international units per milliliter (mIU/mL).

Time frame:
At Month 4
Reported as:
Mean · mIU/mL
Anti-gE Mean Antibody Concentrations
mIU/mLGSK 1437173A F1 GroupGSK 1437173A F2 GroupPlacebo-GSK 1437173A F1 GroupPlacebo Group
Anti-gE Mean Antibody Concentrations131471.10 ± 169644.69102106.14 ± 116349.9463768.06 ± 100839.95840.46 ± 1119.44
SecondaryFrequency of CD4 T-cells Specific for Varicella Zoster Virus (VZV) Antigens

The analysis focused on CD4 T-cells expressing at least 2 cytokines among Interferon gamma \[IFN-γ\], Interleukin 2 \[IL-2\], Tumour Necrosis Factor alpha \[TNF-α\] and/or CD40 Ligand \[CD40L\] as determined by in vitro intracellular cytokine staining (ICS).

Time frame:
At Months 0, 1, 2, 3, 4 and 15
Reported as:
Mean · VZV specific CD4+ T-cells/million Tcells
Frequency of CD4 T-cells Specific for Varicella Zoster Virus (VZV) Antigens
VZV specific CD4+ T-cells/million TcellsGSK 1437173A F1 GroupGSK 1437173A F2 GroupPlacebo-GSK 1437173A F1 GroupPlacebo Group
At Month 0356.11 ± 519.79449.31 ± 637.09343.90 ± 381.20273.91 ± 280.07
At Month 1636.10 ± 886.141205.59 ± 2680.05303.70 ± 383.32486.97 ± 652.18
At Month 23818.03 ± 3773.744466.98 ± 7100.05928.35 ± 1773.80249.91 ± 243.82
At Month 33488.70 ± 4130.593628.20 ± 6682.51887.86 ± 1244.78511.33 ± 909.03
At Month 45359.40 ± 6486.904243.82 ± 6216.734481.70 ± 6761.94279.35 ± 246.06
At Month 153104.65 ± 3543.663298.68 ± 4326.742669.66 ± 3121.01320.39 ± 337.72
SecondaryFrequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines

The analysis focused on CD4 T-cells expressing at least 2 cytokines among Interferon gamma \[IFN-γ\], Interleukin 2 \[IL-2\], Tumour Necrosis Factor alpha \[TNF-α\] and/or CD40 Ligand \[CD40L\] as determined by in vitro intracellular cytokine staining (ICS).

Time frame:
At Months 0, 1, 2, 3 and 15
Reported as:
Mean · gE-specific CD4+ T-cells/million T-cells
Frequency of gE-specific Cluster of Differentiation 4 (CD4) T-cells Expressing at Least 2 Cytokines
gE-specific CD4+ T-cells/million T-cellsGSK 1437173A F1 GroupGSK 1437173A F2 GroupPlacebo-GSK 1437173A F1 GroupPlacebo Group
At Month 0116.53 ± 180.53145.97 ± 217.0183.15 ± 90.3997.48 ± 148.32
At Month 1856.69 ± 1551.941376.95 ± 3358.4991.84 ± 118.22133.85 ± 204.90
At Month 28830.03 ± 9745.119128.95 ± 12539.861528.60 ± 3204.39124.53 ± 160.24
At Month 37111.22 ± 7755.098415.89 ± 12235.84827.83 ± 1508.97158.13 ± 180.84
At Month 156865.36 ± 6557.755900.24 ± 7728.983859.68 ± 4771.0871.03 ± 80.76
SecondaryVaricella Zoster Virus (VZV)-Specific Geometric Mean Antibody Concentrations

Concentrations are presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL).

Time frame:
At Months 0, 1, 2, 3, 4 and 15
Reported as:
Geometric mean · mIU/mL
Varicella Zoster Virus (VZV)-Specific Geometric Mean Antibody Concentrations
mIU/mLGSK 1437173A F1 GroupGSK 1437173A F2 GroupPlacebo-GSK 1437173A F1 GroupPlacebo Group
At Month 0570.1 (393.1 to 826.8)755.1 (479.2 to 1189.9)639.9 (397.5 to 1030.1)659.2 (496.9 to 874.4)
At Month 1922.2 (575.6 to 1477.4)1017.3 (609.6 to 1697.7)562.4 (346.9 to 912.0)729.4 (512.0 to 1039.2)
At Month 24268.5 (2075.7 to 8777.9)4541.3 (2506.4 to 8228.2)702.4 (398.5 to 1238.0)523.5 (351.8 to 779.2)
At Month 33940.7 (1819.0 to 8537.5)4598.3 (2292.6 to 9222.8)558.2 (302.3 to 1030.6)632.7 (374.5 to 1068.8)
At Month 48484.1 (4190.6 to 17176.4)6223.4 (2893.7 to 13384.5)3196.6 (1532.2 to 6668.9)351.9 (207.9 to 595.7)
At Month 151946.5 (1013.4 to 3738.6)2598.2 (1327.4 to 5085.6)930.3 (390.1 to 2218.6)339.4 (159.0 to 724.1)
SecondaryVZV-specific Mean Antibody Concentrations

Concentrations are presented as mean concentrations, expressed in milli-international units per milliliter (mIU/mL).

Time frame:
At Months 0, 1, 2, 3, 4 and 15
Reported as:
Mean · mIU/mL
VZV-specific Mean Antibody Concentrations
mIU/mLGSK 1437173A F1 GroupGSK 1437173A F2 GroupPlacebo-GSK 1437173A F1 GroupPlacebo Group
At Month 0968.22 ± 1466.461340.29 ± 1685.091304.22 ± 1866.32843.07 ± 616.78
At Month 11881.91 ± 2742.851957.16 ± 2438.001089.57 ± 1586.681158.99 ± 1407.26
At Month 215155.95 ± 22198.0310934.78 ± 13735.351506.49 ± 2120.19911.09 ± 1211.24
At Month 313342.90 ± 19278.5712602.99 ± 18030.891227.40 ± 1794.622902.89 ± 10461.29
At Month 423858.74 ± 31173.4516752.32 ± 17738.9510744.24 ± 17397.97753.59 ± 1155.17
At Month 154694.74 ± 5945.235482.75 ± 5769.882956.21 ± 4515.53835.21 ± 947.65
SecondaryAnti-gE Geometric Mean Antibody Concentrations

Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL).

Time frame:
At Months 0, 1, 2, 3 and 15
Reported as:
Geometric mean · mIU/mL
Anti-gE Geometric Mean Antibody Concentrations
mIU/mLGSK 1437173A F1 GroupGSK 1437173A F2 GroupPlacebo-GSK 1437173A F1 GroupPlacebo Group
At Month 0531.2 (402.6 to 700.8)536.2 (304.0 to 945.7)448.0 (289.7 to 692.8)659.9 (470.5 to 925.4)
At Month 11489.7 (847.3 to 2619.0)1288.1 (684.9 to 2422.5)376.1 (239.7 to 590.1)619.3 (424.2 to 904.0)
At Month 211963.0 (4739.4 to 30196.6)11628.8 (5196.6 to 26022.8)1047.8 (564.8 to 1943.9)520.2 (349.3 to 774.8)
At Month 313412.9 (4967.1 to 36219.7)13385.4 (5506.5 to 32537.7)972.6 (520.6 to 1817.2)585.2 (310.0 to 1104.9)
At Month 158052.7 (3333.4 to 19453.7)9165.5 (3796.0 to 22130.1)2968.0 (1184.7 to 7436.1)362.3 (170.7 to 768.7)
SecondaryAnti-gE Mean Antibody Concentrations

Concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and are presented as mean concentrations, expressed in milli-international units per milliliter (mIU/mL).

Time frame:
At Months 0, 1, 2, 3 and 15
Reported as:
Mean · mIU/mL
Anti-gE Mean Antibody Concentrations
mIU/mLGSK 1437173A F1 GroupGSK 1437173A F2 GroupPlacebo-GSK 1437173A F1 GroupPlacebo Group
At Month 0683.78 ± 501.881366.94 ± 2510.90763.58 ± 818.711025.07 ± 1177.35
At Month 14435.62 ± 7776.943812.19 ± 7197.49675.39 ± 776.371016.00 ± 1159.33
At Month 276302.68 ± 118526.3147344.49 ± 78643.102951.78 ± 4785.22927.04 ± 1221.66
At Month 388592.39 ± 133279.2462174.90 ± 94796.542739.11 ± 4458.458908.62 ± 42086.07
At Month 1542128.75 ± 66869.2230938.91 ± 45130.7916564.63 ± 30523.281091.74 ± 1585.07
SecondaryNumber of Subjects With Confirmed Herpes Zoster (HZ) Cases

A suspected case of HZ could be confirmed by PCR and/or by clinical review of the GSK physician responsible for the study. Rash lesion samples collected from subjects clinically diagnosed as having a suspected case of HZ were tested by by polymerase chain reaction (PCR) using standardized and validated procedures for the laboratory diagnosis of HZ. If the PCR specimen was inadequate or was missing, suspected HZ cases were to be classified as 'a confirmed case of HZ' or 'not a case of HZ' based on the determination by the GSK responsible physician of the study.

Time frame:
During the entire study period (from Day 0 to Month 15)
Reported as:
Count of participants · Participants
Number of Subjects With Confirmed Herpes Zoster (HZ) Cases
ParticipantsGSK 1437173A F1 GroupGSK 1437173A F2 GroupPlacebo-GSK 1437173A F1 GroupPlacebo Group
Number of Subjects With Confirmed Herpes Zoster (HZ) Cases0202

Adverse events

Collected over Solicited local/general symptoms: during the 7-day post-vaccination period (Days 0-6); Unsolicited AEs: during the 30-day post-vaccination period (Days 0-29); SAEs: during the entire study period (Day 0 - Month 15).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GSK 1437173A F1 Group3/30 (10%)6/30 (20%)29/30 (96.7%)
GSK 1437173A F2 Group1/29 (3.4%)9/29 (31%)27/29 (93.1%)
Placebo-GSK 1437173A F1 Group2/31 (6.5%)10/31 (32.3%)29/31 (93.5%)
Placebo Group3/30 (10%)8/30 (26.7%)21/30 (70%)
Most frequent serious events
Showing 10 of 44
Most frequent serious events
EventGSK 1437173A F1 GroupGSK 1437173A F2 GroupPlacebo-GSK 1437173A F1 GroupPlacebo Group
PneumoniaInfections and infestations0/301/292/312/30
PyrexiaGeneral disorders0/300/292/310/30
CellulitisInfections and infestations0/300/292/310/30
Multiple myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/301/292/311/30
CoughRespiratory, thoracic and mediastinal disorders0/300/292/310/30
Febrile neutropeniaBlood and lymphatic system disorders0/301/291/310/30
PancytopeniaBlood and lymphatic system disorders0/301/290/310/30
Clostridial infectionInfections and infestations0/301/290/310/30
Clostridium difficile colitisInfections and infestations0/301/290/310/30
UrosepsisInfections and infestations0/301/290/310/30
Most frequent other events
Showing 10 of 32
Most frequent other events
EventGSK 1437173A F1 GroupGSK 1437173A F2 GroupPlacebo-GSK 1437173A F1 GroupPlacebo Group
PainGeneral disorders27/3022/2924/317/30
FatigueGeneral disorders18/3018/2925/3110/30
MyalgiaMusculoskeletal and connective tissue disorders21/3018/2923/318/30
HeadacheNervous system disorders13/303/2912/316/30
PyrexiaGeneral disorders12/309/2912/314/30
Gastrointestinal disorderGastrointestinal disorders10/307/2911/314/30
ErythemaSkin and subcutaneous tissue disorders6/307/297/311/30
SwellingGeneral disorders6/304/294/310/30
Oropharyngeal painRespiratory, thoracic and mediastinal disorders5/301/291/313/30
CoughRespiratory, thoracic and mediastinal disorders3/303/293/314/30

Baseline characteristics

Age, Continuous
Age, Continuous(Years)GSK 1437173A F1 GroupGSK 1437173A F2 GroupPlacebo-GSK 1437173A F1 GroupPlacebo GroupTotal
Mean53.1 ± 12.256.0 ± 11.457.8 ± 6.857.3 ± 8.656.1 ± 10.0
Sex: Female, Male
Sex: Female, Male(Participants)GSK 1437173A F1 GroupGSK 1437173A F2 GroupPlacebo-GSK 1437173A F1 GroupPlacebo GroupTotal
Female129101142
Male1820211978
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GSK 1437173A F1 GroupGSK 1437173A F2 GroupPlacebo-GSK 1437173A F1 GroupPlacebo GroupTotal
Race/Ethnicity — African Heritage/African American22116
Race/Ethnicity — American Indian or Alaskan Native01001
Race/Ethnicity — Asian-Central/South Asian Heritage00011
Race/Ethnicity — Asian-East Asian Heritage00022
Race/Ethnicity — Asian-Japanese Heritage10001
Race/Ethnicity — Other22048
Race/Ethnicity — White-Arabic/North African Heritage10001
Race/Ethnicity — White-Caucasian/European Heritage24243022100
08

Study locations

11 sites
  • GSK Investigational Site
    Little Rock, Arkansas 72205, United States
  • GSK Investigational Site
    Duarte, California 91010, United States
  • GSK Investigational Site
    Frisco, California 94143, United States
  • GSK Investigational Site
    Boston, Massachusetts 02115, United States
  • GSK Investigational Site
    Minnesota, Minnesota 55455, United States
  • GSK Investigational Site
    Rochester, Minnesota 55905, United States
  • GSK Investigational Site
    New York, New York 10065, United States
  • GSK Investigational Site
    Chapel Hill, North Carolina 27599, United States
  • GSK Investigational Site
    Durham, North Carolina 27705, United States
  • GSK Investigational Site
    Cleveland, Ohio 44195, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19104, United States
09

References and documents

Publications

  • Stadtmauer EA, Sullivan KM, Marty FM, Dadwal SS, Papanicolaou GA, Shea TC, Mossad SB, Andreadis C, Young JA, Buadi FK, El Idrissi M, Heineman TC, Berkowitz EM. A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood. 2014 Nov 6;124(19):2921-9. doi: 10.1182/blood-2014-04-573048. Epub 2014 Sep 18. PubMed 25237196 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2009 to primary completion in Apr 2011, 21 months.

Results were first posted in Dec 2017, 6 years 7 months after primary completion. A results delay was requested in Jun 2011.

Of 22 phase 2 interventional studies under Herpes Zoster, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 27. This study's 21 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2009
First posted
Jun 15, 2009
StartActual
Jul 14, 2009
Primary completionActual
Apr 26, 2011
CompletionActual
Mar 21, 2012
Results delay requested
Jun 1, 2011
Results first posted
Dec 12, 2017
Last update
Dec 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00920218
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 15, 2009
Start date
Jul 14, 2009
Primary completion
Apr 26, 2011
Completion
Mar 21, 2012
Results posted
Dec 12, 2017
Last update
Dec 12, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Shingrix

Start the discussion